fluorodeoxyglucose f18 has been researched along with masitinib in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Benatsou, B; Bidault, S; Blay, JY; Chami, L; Chebil, M; Cioffi, A; Koscielny, S; Lassau, N; Le Cesne, A; Massard, C | 1 |
1 trial(s) available for fluorodeoxyglucose f18 and masitinib
| Article | Year |
|---|---|
Quantitative functional imaging by dynamic contrast enhanced ultrasonography (DCE-US) in GIST patients treated with masatinib.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Blood Volume; Contrast Media; Female; Fluorodeoxyglucose F18; France; Gastrointestinal Stromal Tumors; Humans; Male; Middle Aged; Molecular Targeted Therapy; Perfusion Imaging; Phospholipids; Piperidines; Positron-Emission Tomography; Predictive Value of Tests; Prospective Studies; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyridines; Radiopharmaceuticals; Receptor, Fibroblast Growth Factor, Type 3; Receptors, Platelet-Derived Growth Factor; Sulfur Hexafluoride; Thiazoles; Time Factors; Tomography, X-Ray Computed; Treatment Outcome; Ultrasonography | 2012 |